GB2411116A - Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative - Google Patents

Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative Download PDF

Info

Publication number
GB2411116A
GB2411116A GB0511750A GB0511750A GB2411116A GB 2411116 A GB2411116 A GB 2411116A GB 0511750 A GB0511750 A GB 0511750A GB 0511750 A GB0511750 A GB 0511750A GB 2411116 A GB2411116 A GB 2411116A
Authority
GB
United Kingdom
Prior art keywords
phosphonate
vitamin
bis
alendronate
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0511750A
Other versions
GB2411116B (en
GB0511750D0 (en
Inventor
Moshe Flashner-Barak
Itzhak E Lerner
Vered Rosenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of GB0511750D0 publication Critical patent/GB0511750D0/en
Publication of GB2411116A publication Critical patent/GB2411116A/en
Application granted granted Critical
Publication of GB2411116B publication Critical patent/GB2411116B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention provides a method of increasing the bioavailability of a bis-phosphonate comprising administering an effective predose of a vitamin D derivative, such as alphacalcidol or calcitriol, and after a time interval, administering a therapeutic dose of bis-phosphonate, such as alendronate. The present invention also relates to the use of vitamin D derivatives and bisphosphonates for the manufacture of medicaments for treating osteoporosis, metastatic bone disease, and Paget's disease.

Description

GB 2411116 A continuation (74) Agent and/or Address for Service: D Young &
Co Holborn, LONDON, EC1N 2DY, United Kingdom
GB0511750A 2002-12-16 2003-12-16 Increasing the bioavailability of alendronate by predose administration of alphacalcidol Expired - Fee Related GB2411116B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43368502P 2002-12-16 2002-12-16
US46020603P 2003-04-02 2003-04-02
PCT/US2003/040174 WO2004058235A2 (en) 2002-12-16 2003-12-16 Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative

Publications (3)

Publication Number Publication Date
GB0511750D0 GB0511750D0 (en) 2005-07-20
GB2411116A true GB2411116A (en) 2005-08-24
GB2411116B GB2411116B (en) 2009-04-29

Family

ID=32685268

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0511750A Expired - Fee Related GB2411116B (en) 2002-12-16 2003-12-16 Increasing the bioavailability of alendronate by predose administration of alphacalcidol

Country Status (7)

Country Link
JP (3) JP2006514695A (en)
AU (1) AU2003300984A1 (en)
DE (1) DE10393906T5 (en)
GB (1) GB2411116B (en)
HK (1) HK1078802A1 (en)
IL (1) IL169127A0 (en)
WO (1) WO2004058235A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3095447T1 (en) 2006-02-03 2022-02-28 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US7749536B2 (en) * 2006-02-14 2010-07-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
ES2670029T3 (en) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D replenishment agent and vitamin D hormone replacement agent
WO2008074145A1 (en) * 2006-12-20 2008-06-26 Genpharm Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
CA2671727C (en) * 2006-12-20 2016-02-16 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
PL2148661T3 (en) 2007-04-25 2013-07-31 Cytochroma Inc Oral controlled release compositions comprising vitamin d compound and waxy carrier
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
JP5444212B2 (en) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド Method for treating vitamin D deficiency and deficiency
EP2148683A4 (en) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
ES2593356T3 (en) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Useful methods, compositions, uses and kits for vitamin D deficiency and related disorders
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
CN114681468A (en) 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 Adjunctive therapy with 25-hydroxyvitamin D
KR20230056790A (en) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 Methods of vitamin d treatment
CN109364034B (en) * 2018-11-26 2021-05-04 正大制药（青岛）有限公司 Calcitriol preparation and preparation method thereof
CN116211818B (en) * 2023-03-10 2024-04-09 菲洋生物科技(吉林)有限公司 Tablet containing alendronate sodium and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028564A1 (en) * 1999-10-20 2001-04-26 Yuyu Industrial Co., Ltd. Pharmaceutical compositions and preparations for treatment of metabolic bone disease
WO2003007916A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028564A1 (en) * 1999-10-20 2001-04-26 Yuyu Industrial Co., Ltd. Pharmaceutical compositions and preparations for treatment of metabolic bone disease
WO2003007916A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Erben R G et al, Journal of Bone and Mineral Research, (2002), 17(8), 1498-1511 *
Frediani B et al, Clinical Drug Investigation, (1998), 15(3), 235-244 *
Gertz B et al, Clinical Pharmacology & Therapeutics, (1995), 58(3), 288-298 *
Malavolta N et al, International Journal of Tissue Reactions, (1999), 21(2), 51-59 *
Nasud T et al, Annals of the Rheumatic Diseases, (1998), 57(6), 346-349 *
Nuti R et al, Clinical Drug Investigation, (2000), 19(1), 55-61 *

Also Published As

Publication number Publication date
WO2004058235A3 (en) 2005-02-24
JP2006514695A (en) 2006-05-11
WO2004058235A2 (en) 2004-07-15
HK1078802A1 (en) 2006-03-24
AU2003300984A8 (en) 2004-07-22
AU2003300984A1 (en) 2004-07-22
JP2014205711A (en) 2014-10-30
JP2011241221A (en) 2011-12-01
DE10393906T5 (en) 2006-01-12
IL169127A0 (en) 2009-02-11
GB2411116B (en) 2009-04-29
GB0511750D0 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
GB2411116A (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
HUP0204114A2 (en) Pharmaceutical parenteral composition containing biphosphonate
UA84277C2 (en) Sustained-release tramadol formulations with 24-hour efficacy
MXPA03007837A (en) Compositions for delivering bisphosphonates.
GEP20063895B (en) Platinum derivative pharmaceutical formulations
MXPA04012998A (en) Tricyclic steroid hormone nuclear receptor modulators.
YU68199A (en) Pharmaceutical formulations containing voriconazole
HK1076605A1 (en) Formulations
IL159996A0 (en) Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
BG104727A (en) Pharmaceutical composition of topiramate
HUP0203168A2 (en) Compositions for mucosal delivery
DK1033981T3 (en) Formulations and methods for reducing the toxicity of antineoplastic agents
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
RU2008103617A (en) BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS
JO2663B1 (en) High dose ibandronate formulation
EP1420827B8 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
UA90504C2 (en) Novel drugs for treating respiratory diseases
GB2446341A (en) Method and system for transdermal drug delivery
TWI319713B (en) Sustained-release tramadol formulations with 24-hour efficacy
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
PT1392325E (en) METHOD OF ADMINISTRATION OF BIFPHOSPHONATES BY INHALATION IN TREATMENT OR PREVENTION OF OSHA REOPSORCA AND OSTEOPOROSIS
BRPI9916820B8 (en) a composition comprising 9 [2 [[bis [(pivaloyloxy) methyl] phosphono] methoxy] ethyl] adenine, tablet or capsule and method

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078802

Country of ref document: HK

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20090318

Free format text: EXTENSION APPLICATION

Effective date: 20090311

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078802

Country of ref document: HK

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20151216